- Home
- ACIU vs AEYE Comparison
ACIU vs AEYE Comparison
Compare ACIU & AEYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- AEYE
- Stock Information
- Founded
- ACIU 2003
- AEYE 2005
- Country
- ACIU Switzerland
- AEYE United States
- Employees
- ACIU N/A
- AEYE 114
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- AEYE Computer Software: Prepackaged Software
- Sector
- ACIU Health Care
- AEYE Technology
- Exchange
- ACIU Nasdaq
- AEYE Nasdaq
- Market Cap
- ACIU 332.4M
- AEYE 205.3M
- IPO Year
- ACIU 2016
- AEYE N/A
- Fundamental
- Price
- ACIU $2.67
- AEYE $16.98
- Analyst Decision
- ACIU Strong Buy
- AEYE Strong Buy
- Analyst Count
- ACIU 2
- AEYE 4
- Target Price
- ACIU $12.00
- AEYE $30.13
- AVG Volume (30 Days)
- ACIU 132.5K
- AEYE 381.7K
- Earning Date
- ACIU 11-05-2024
- AEYE 11-07-2024
- Dividend Yield
- ACIU N/A
- AEYE N/A
- EPS Growth
- ACIU N/A
- AEYE N/A
- EPS
- ACIU N/A
- AEYE N/A
- Revenue
- ACIU $48,505,404.00
- AEYE $33,348,000.00
- Revenue This Year
- ACIU $85.33
- AEYE $14.64
- Revenue Next Year
- ACIU $80.69
- AEYE $21.65
- P/E Ratio
- ACIU N/A
- AEYE N/A
- Revenue Growth
- ACIU 4097200.00
- AEYE 6.94
- 52 Week Low
- ACIU $2.25
- AEYE $4.26
- 52 Week High
- ACIU $5.14
- AEYE $34.85
- Technical
- Relative Strength Index (RSI)
- ACIU 27.22
- AEYE 35.81
- Support Level
- ACIU $2.63
- AEYE $16.24
- Resistance Level
- ACIU $3.07
- AEYE $18.00
- Average True Range (ATR)
- ACIU 0.15
- AEYE 1.45
- MACD
- ACIU -0.04
- AEYE -0.20
- Stochastic Oscillator
- ACIU 8.96
- AEYE 14.55
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's, and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.